版本:
中国

BRIEF-Seattle Genetics discontinues Phase 3 trial of vadastuximab talirine

June 19 Seattle Genetics Inc:

* Seattle Genetics discontinues Phase 3 cascade trial of vadastuximab talirine (SGN-CD33A) in frontline acute myeloid leukemia

* Seattle Genetics discontinues Phase 3 cascade trial of vadastuximab talirine (SGN-CD33A) in frontline acute myeloid leukemia

* Seattle Genetics Inc - will closely review data and consult with FDA to determine future plans for vadastuximab talirine development program

* Seattle Genetics - data indicated higher rate of deaths, including fatal infections in vadastuximab talirine-containing arm versus control arm of trial

* Says ‍based on available data, safety concerns in this trial do not appear related to hepatotoxicity​

* Seattle Genetics Inc - suspending patient enrollment and treatment in all of its vadastuximab talirine clinical trials

* Seattle Genetics - on track to advance enfortumab vedotin into a pivotal trial in metastatic urothelial cancer in H2 2017 under collaboration with Astellas Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐